Guideline-concordant therapy and outcomes in healthcare-associated pneumonia

R. T. Attridge, Chris Frei, Marcos Restrepo, K. A. Lawson, L. Ryan, M. J V Pugh, Antonio R Anzueto, E. M. Mortensen

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Original languageEnglish
Pages (from-to)878-887
Number of pages10
JournalEuropean Respiratory Journal
Volume38
Issue number4
DOIs
StatePublished - Oct 1 2011

Fingerprint

Pneumonia
Guidelines
Delivery of Health Care
Therapeutics
Propensity Score
Mortality
Logistic Models
Veterans Health
United States Department of Veterans Affairs
Critical Illness
Cohort Studies
Anti-Bacterial Agents
Survival

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Attridge, R. T., Frei, C., Restrepo, M., Lawson, K. A., Ryan, L., Pugh, M. J. V., ... Mortensen, E. M. (2011). Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. European Respiratory Journal, 38(4), 878-887. https://doi.org/10.1183/09031936.00141110

Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. / Attridge, R. T.; Frei, Chris; Restrepo, Marcos; Lawson, K. A.; Ryan, L.; Pugh, M. J V; Anzueto, Antonio R; Mortensen, E. M.

In: European Respiratory Journal, Vol. 38, No. 4, 01.10.2011, p. 878-887.

Research output: Contribution to journalArticle

Attridge, R. T. ; Frei, Chris ; Restrepo, Marcos ; Lawson, K. A. ; Ryan, L. ; Pugh, M. J V ; Anzueto, Antonio R ; Mortensen, E. M. / Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. In: European Respiratory Journal. 2011 ; Vol. 38, No. 4. pp. 878-887.
@article{ef4a846d058c48778a1ea3204f5b4809,
title = "Guideline-concordant therapy and outcomes in healthcare-associated pneumonia",
abstract = "Healthcare-associated pneumonia (HCAP) guidelines were first proposed in 2005 but have not yet been validated. The objective of this study was to compare 30-day mortality in HCAP patients treated with either guideline-concordant (GC)-HCAP therapy or GC communityacquired pneumonia (CAP) therapy. We performed a population-based cohort study of >150 hospitals in the US Veterans Health Administration. Patients were included if they had one or more HCAP risk factors and received antibiotic therapy within 48 h of admission. Critically ill patients were excluded. Independent risk factors for 30-day mortality were determined in a generalised linear mixed-effect model, with admitting hospital as a random effect. Propensity scores for the probability of receiving GC-HCAP therapy were calculated and incorporated into a second logistic regression model. A total of 15,071 patients met study criteria and received GC-HCAP therapy (8.0{\%}), GC-CAP therapy (75.7{\%}) or non-GC therapy (16.3{\%}). The strongest predictors of 30-day mortality were recent hospital admission (OR 2.49, 95{\%} CI 2.12-2.94) and GC-HCAP therapy (OR 2.18, 95{\%} CI 1.86-2.55). GC-HCAP therapy remained an independent risk factor for 30-day mortality (OR 2.12, 95{\%} CI 1.82-2.48) in the propensity score analysis. In nonsevere HCAP patients, GC-HCAP therapy is not associated with improved survival compared with GC-CAP therapy.",
keywords = "Drug resistance, Guidelines for management of pneumonia, Health outcomes, Pneumonia",
author = "Attridge, {R. T.} and Chris Frei and Marcos Restrepo and Lawson, {K. A.} and L. Ryan and Pugh, {M. J V} and Anzueto, {Antonio R} and Mortensen, {E. M.}",
year = "2011",
month = "10",
day = "1",
doi = "10.1183/09031936.00141110",
language = "English",
volume = "38",
pages = "878--887",
journal = "Acta tuberculosea Scandinavica",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "4",

}

TY - JOUR

T1 - Guideline-concordant therapy and outcomes in healthcare-associated pneumonia

AU - Attridge, R. T.

AU - Frei, Chris

AU - Restrepo, Marcos

AU - Lawson, K. A.

AU - Ryan, L.

AU - Pugh, M. J V

AU - Anzueto, Antonio R

AU - Mortensen, E. M.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Healthcare-associated pneumonia (HCAP) guidelines were first proposed in 2005 but have not yet been validated. The objective of this study was to compare 30-day mortality in HCAP patients treated with either guideline-concordant (GC)-HCAP therapy or GC communityacquired pneumonia (CAP) therapy. We performed a population-based cohort study of >150 hospitals in the US Veterans Health Administration. Patients were included if they had one or more HCAP risk factors and received antibiotic therapy within 48 h of admission. Critically ill patients were excluded. Independent risk factors for 30-day mortality were determined in a generalised linear mixed-effect model, with admitting hospital as a random effect. Propensity scores for the probability of receiving GC-HCAP therapy were calculated and incorporated into a second logistic regression model. A total of 15,071 patients met study criteria and received GC-HCAP therapy (8.0%), GC-CAP therapy (75.7%) or non-GC therapy (16.3%). The strongest predictors of 30-day mortality were recent hospital admission (OR 2.49, 95% CI 2.12-2.94) and GC-HCAP therapy (OR 2.18, 95% CI 1.86-2.55). GC-HCAP therapy remained an independent risk factor for 30-day mortality (OR 2.12, 95% CI 1.82-2.48) in the propensity score analysis. In nonsevere HCAP patients, GC-HCAP therapy is not associated with improved survival compared with GC-CAP therapy.

AB - Healthcare-associated pneumonia (HCAP) guidelines were first proposed in 2005 but have not yet been validated. The objective of this study was to compare 30-day mortality in HCAP patients treated with either guideline-concordant (GC)-HCAP therapy or GC communityacquired pneumonia (CAP) therapy. We performed a population-based cohort study of >150 hospitals in the US Veterans Health Administration. Patients were included if they had one or more HCAP risk factors and received antibiotic therapy within 48 h of admission. Critically ill patients were excluded. Independent risk factors for 30-day mortality were determined in a generalised linear mixed-effect model, with admitting hospital as a random effect. Propensity scores for the probability of receiving GC-HCAP therapy were calculated and incorporated into a second logistic regression model. A total of 15,071 patients met study criteria and received GC-HCAP therapy (8.0%), GC-CAP therapy (75.7%) or non-GC therapy (16.3%). The strongest predictors of 30-day mortality were recent hospital admission (OR 2.49, 95% CI 2.12-2.94) and GC-HCAP therapy (OR 2.18, 95% CI 1.86-2.55). GC-HCAP therapy remained an independent risk factor for 30-day mortality (OR 2.12, 95% CI 1.82-2.48) in the propensity score analysis. In nonsevere HCAP patients, GC-HCAP therapy is not associated with improved survival compared with GC-CAP therapy.

KW - Drug resistance

KW - Guidelines for management of pneumonia

KW - Health outcomes

KW - Pneumonia

UR - http://www.scopus.com/inward/record.url?scp=80053513739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053513739&partnerID=8YFLogxK

U2 - 10.1183/09031936.00141110

DO - 10.1183/09031936.00141110

M3 - Article

C2 - 21436359

AN - SCOPUS:80053513739

VL - 38

SP - 878

EP - 887

JO - Acta tuberculosea Scandinavica

JF - Acta tuberculosea Scandinavica

SN - 0903-1936

IS - 4

ER -